This series of four webinars will cover all aspects of diagnosis and treatment of the major short stature disorders. The definition and diagnosis of short stature will be described, together with the most common syndromes that have growth deficiency as one of their symptoms, and notably those which are approved by the FDA or EMA for treatment with recombinant human growth hormone (rhGH). rhGH therapy will be described in detail from its aims and objectives, initiation of therapy, dosage and monitoring to the responses in the most common disorders. Therapeutic outcome will be described. Many children (and adults) can be on rhGH therapy for extended periods of time, raising the issue of safety. This will be discussed, as will adherence to treatment, and the use of rhGH into adulthood, particularly in patients with severe GH deficiency and Prader-Willi syndrome.
CONTINUING MEDICAL EDUCATION
Each webinar will be submitted for CME accreditation.
CHAIRMAN
Martin Savage
Professor Emeritus of Pediatric Endocrinology
William Harvey Research Institute
Bars and the London School of Medicine and Dentistry
Queen Mary, University of London, UK
WEBINARS’ DATES AND TITLES:
Thursday, 9 December 2021
Webinar n. 1: “The diagnostic approach to short stature”
Thursday, 13 January 2022
Webinar n. 2: “True pathological short stature: Features and implications compared to variants of normal growth”
Thursday, 17 February 2022
Webinar n. 3: “Indications and potential benefit of growth hormone therapy”
Thursday, 17 March 2022
Webinar n. 4: “Key components of growth hormone therapy”
